Allo-Glue™ Platform

Breakthroughs in Molecular Glue Discovery and Design

Our proprietary chemical biology platform enables unprecedented, high throughput and high complexity drug ligand screening and genome-scale mapping of drug-protein interactions directly in living cells. This is further complemented by a suite of computational tools, numerical and machine learning models, and rational drug design for molecular glues.

Monovalent glues have unique potential to address historically elusive disease targets. We apply these capabilities to a broad spectrum of small molecule discovery and optimization paradigms, with a major focus on monovalent glues that act through allosteric mechanisms (Allo-Glues™) to reach, modulate, inhibit or degrade novel and traditionally hard-to-drug disease targets. We are pursuing a diversity of molecular glues in our pipelines and strategic partnerships, including with Novartis and Genentech.

For monovalent glues, and as disease protein degraders, our platform enables three major approaches at unique scale:

• Ligase centric approach: determining the ability of a ligase ligand (candidate glue) to promote interactions with any one of ~20,000 proteins encoded by the human genome
• Reverse target centric approach: determining the ability of a target ligand to differentially promote interaction of its target with any one of 400+ qualified ligases to promote its self-degradation
• Target centric approach: discovery of glues, through chemical diversity library screens, that promote interaction of a target of interest with any one of a set of qualified ligases